RA 123456

Drug Profile

RA 123456

Alternative Names: Ca/calmodulin kinase II; CaMKII modulator

Latest Information Update: 30 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi
  • Developer Sanofi; University Hospital Regensburg
  • Class
  • Mechanism of Action Calmodulin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atrial fibrillation; Heart failure

Most Recent Events

  • 27 Aug 2016 Preclinical trials in Atrial fibrillation and Heart failure in USA and Germany before August 2016 (PO)
  • 27 Aug 2016 Pharmacodynamics data from preclinical studies in Heart failure and Atrial fibrillation presented at the Annual Congress of the European Society of Cardiology (ESC Congress 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top